Many potent new medicines pose a host of challenges for drug companies trying to copy and sell similar versions on the cheap. Can those companies find a sustainable path forward, or will patients get left stuck paying exorbitant prices?
Guests:
Christine Baeder, MBA, President, Apotex USA
Alfred Engelberg, JD, retired attorney and former counsel to the Generic Pharmaceutical Industry Association
Jeremy Greene, MD, PhD, Professor of Medicine and the History of Medicine, Johns Hopkins University
Candy Meyer, Patient
Bhaven Sampat, PhD, Professor, Arizona State University School for the Future of Innovation in Society
Marta Wosińska, PhD, Senior Fellow, Brookings Institution
Leslie Walker, Senior Reporter/Producer, Tradeoffs
Learn more and read a full transcript on our website.
Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.
Support this type of journalism today, with a gift.
","author_name":"Tradeoffs"}